A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer
Lee, E.; Archasappawat, S.; Ji, K.; Pena, J.; Fernandez-Vega, V.; Gangaraju, R.; Beesabathuni, N. S.; Kim, M.; Tian, Q.; Shah, P.; Scampavia, L.; Spicer, T.; Hwang, C.-i.
Show abstract
Pancreatic cancer is one of the deadliest diseases in human malignancies. Among total pancreatic cancer patients, [~]10% of patients are categorized as familial pancreatic cancer (FPC) patients, carrying germline mutations of the genes involved in DNA repair pathways (e.g., BRCA2). Personalized medicine approaches tailored toward patients mutations would improve patients outcome. To identify novel vulnerabilities of BRCA2-deficient pancreatic cancer, we generated isogenic Brca2-deficient murine pancreatic cancer cell lines and performed high-throughput drug screens. High-throughput drug screening revealed that Brca2-deficient cells are sensitive to Bromodomain and Extraterminal Motif (BET) inhibitors, suggesting that BET inhibition might be a potential therapeutic approach. We found that BRCA2 deficiency increased autophagic flux, which was further enhanced by BET inhibition in Brca2-deficient pancreatic cancer cells, resulting in autophagy-dependent cell death. Our data suggests that BET inhibition can be a novel therapeutic strategy for BRCA2-deficient pancreatic cancer.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Targeting glucose metabolism sensitizes pancreatic cancer to MEK inhibition 97%
- Targeting the dependence on PIK3C3-mTORC1 signaling in dormancy-prone breast cancer cells blunts metastasis initiation 97%
- NRF2 translation block by inhibition of cap-dependent initiation sensitizes lymphoma cells to ferroptosis and CAR-T immunotherapy 96%
Similar papers in this journal
- The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. 95%
- Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels 95%
- CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors 95%
Similar papers in this journal
- Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer 96%
- Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblastdriven nutritional support and immunosuppression 95%
- Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression 95%
Similar papers in this journal
- PIM Kinases Alter Mitochondrial Dynamics and Chemosensitivity in Lung Cancer 95%
- Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling 95%
- Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.